The first gene therapy that can be applied to the skin was able to heal the blistering wounds endured by children with a structural skin deficiency. In addition to being the first topical gene therapy, the treatment from Krystal Biotech would be the first gene therapy that can be repeated because it doesn’t trigger an immune response.
Shares of Krystal (ticker: KRYS) were up 120% to $88 in Monday midmorning trading on the company’s report of initial data from the pivotal trial of its Vyjuvek treatment. Earlier in the morning,…